Show simple item record

dc.contributor.authorAlkan, H. Furkan
dc.contributor.authorLuengo, Alba
dc.contributor.authorLau, Allison N.
dc.contributor.authorLewis, Caroline A.
dc.contributor.authorVander Heiden, Matthew G.
dc.date.accessioned2020-04-29T17:46:38Z
dc.date.available2020-04-29T17:46:38Z
dc.date.issued2018-11
dc.identifier.issn1550-4131
dc.identifier.urihttps://hdl.handle.net/1721.1/124929
dc.description.abstractMitochondrial function is important for aspartate biosynthesis in proliferating cells. Here, we show that mitochondrial aspartate export via the aspartate-glutamate carrier 1 (AGC1) supports cell proliferation and cellular redox homeostasis. Insufficient cytosolic aspartate delivery leads to cell death when TCA cycle carbon is reduced following glutamine withdrawal and/or glutaminase inhibition. Moreover, loss of AGC1 reduces allograft tumor growth that is further compromised by treatment with the glutaminase inhibitor CB-839. Together, these findings argue that mitochondrial aspartate export sustains cell survival in low-glutamine environments and AGC1 inhibition can synergize with glutaminase inhibition to limit tumor growth. Alkan et al. show that, under conditions in which cytosolic glutamine is limiting, mitochondrial aspartate export, via the aspartate-glutamate carrier 1 (AGC1), supports cell proliferation and cellular redox homeostasis and that AGC1 inhibition can synergize with glutaminase inhibition to limit tumor growth.en_US
dc.description.sponsorshipAustrian Science Fund (Grant FWF SFB LIPTOX F3018)en_US
dc.description.sponsorshipAustrian Science Fund (Grant P27108, P28854)en_US
dc.description.sponsorshipAustrian Science Fund (Grant W1226 DK)en_US
dc.description.sponsorshipNational Cancer Institute (U.S.) (Grant P30 CA1405141)en_US
dc.description.sponsorshipNational Cancer Institute (U.S.) (Grant R01 CA168653)en_US
dc.description.sponsorshipNational Science Foundation (U.S.) (Grant GRFP DGE-1122374)en_US
dc.description.sponsorshipNational Science Foundation (U.S.) (Grant T32GM007287)en_US
dc.description.sponsorshipDamon Runyon Cancer Research Foundation (Grant DRG-2241-15)en_US
dc.language.isoen
dc.publisherElsevier BVen_US
dc.relation.isversionof10.1016/j.cmet.2018.07.021en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.sourcePMCen_US
dc.titleCytosolic Aspartate Availability Determines Cell Survival When Glutamine Is Limitingen_US
dc.typeArticleen_US
dc.identifier.citationAlkan, H. Furkan et al. “Cytosolic Aspartate Availability Determines Cell Survival When Glutamine Is Limiting.” Cell Metabolism 28 (2018): 706-720 © 2018 The Author(s)en_US
dc.contributor.departmentWhitehead Institute for Biomedical Researchen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.relation.journalCell Metabolismen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2020-01-30T18:45:41Z
dspace.date.submission2020-01-30T18:45:43Z
mit.journal.volume28en_US
mit.journal.issue5en_US
mit.licensePUBLISHER_CC
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record